Transrectal high-intensity focused ultrasound in the treatment of localized prostate cancer.
The literature concerning the efficacy and safety of transrectal high-intensity focused ultrasound (HIFU) for the treatment of localized prostate cancer still comprises a relatively small number of articles. The main studies have been published by four teams using an apparatus available in Europe for several years. The recently presented results of the European Multicentre Study and the study by Gelet and associates based on 242 patients with a follow-up of more than 1 year show that HIFU is a valid alternative for the management of welldifferentiated and moderately differentiated localized prostate cancer with an initial PSA </=15 ng/mL in men with a life expectancy >10 years. In two studies, the combination of transurethral resection of the prostate and HIFU limited the risk of postoperative urinary retention without inducing a higher complication rate. In a series of patients presenting recurrence after external-beam radiotherapy, HIFU was found to be a useful therapy, with >80% negative biopsies. The best indications for HIFU are men over the age of 65, those who are not candidates for radical prostatectomy, obese patients, or patients with comorbidities likely to make surgery more difficult. The learning curve for this technique is relatively short, between 10 and 15 patients, for urologists experienced in transrectal ultrasonography. One of the advantages of HIFU is that it can be repeated in the case of recurrence or to re-treat a prostatic site, it involves no radiation, and patients do not suffer from long-term irritative urinary symptoms.
Rebillard
Xavier
X
Clinique Beausoleil, Montpellier, France.
Gelet
Albert
A
Davin
Jean Louis
JL
Soulie
Michel
M
Prapotnich
Dominique
D
Cathelineau
Xavier
X
Rozet
François
F
Vallancien
Guy
G
D000368:Aged; D000369:Aged, 80 and over; D000818:Animals; D017321:Clinical Trials, Phase I as Topic; D004195:Disease Models, Animal; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D017430:Prostate-Specific Antigen / Q000097:blood*; D011471:Prostatic Neoplasms / Q000000981:diagnostic imaging / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D012007:Rectum; D018570:Risk Assessment; D015996:Survival Rate; D016896:Treatment Outcome; D014464:Ultrasonic Therapy / Q000379:methods*; D014463:Ultrasonography
D017430:Prostate-Specific Antigen